Filgrastim

Generic Name
Filgrastim
Brand Names
Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
Drug Type
Biotech
Chemical Formula
-
CAS Number
121181-53-1
Unique Ingredient Identifier
PVI5M0M1GW
Background

Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from the bone marrow. Filgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood. It has a number of therapeutic uses, including the management and prevention of infections and febrile neutropenia in patients receiving myelosuppressive chemotherapy or radiation therapy. It is also used to manage severe chronic neutropenia and mobilize hematopoietic progenitor cells to the peripheral blood for collection by leukapheresis in patients undergoing peripheral blood progenitor cell collection and therapy.

Filgrastim was approved in the US in 1991 and there are biosimilars available with similar therapeutic indications. Tbo-filgrastim was approved by the FDA on August 29, 2012. Filgrastim-sndz was approved on March 6, 2015 and filgrastim-ayow was approved on March 2, 2022. A long-acting, pegylated G-CSF, pegfilgrastim, was made available to increase the duration of action of the drug.

Indication

Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.

Filgrastim is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia.

Filgrastim is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.

Filgrastim is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.

Filgrastim is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia.

Filgrastim is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.

Associated Conditions
Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
Associated Therapies
Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy

SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia

First Posted Date
2007-06-18
Last Posted Date
2008-11-19
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
200
Registration Number
NCT00487448
Locations
🇪🇸

Hospital Germans Trias i Pujol, Badalona, Spain

🇪🇸

Hospital Universitario La Paz, Madrid, Spain

🇪🇸

Hospital del Mar, Barcelona, Spain

and more 12 locations

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

First Posted Date
2007-05-04
Last Posted Date
2021-01-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
72
Registration Number
NCT00469014
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia

First Posted Date
2007-03-12
Last Posted Date
2015-08-25
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT00446173
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy

First Posted Date
2007-03-06
Last Posted Date
2024-03-04
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT00020371
Locations
🇺🇸

Medicine Branch, Bethesda, Maryland, United States

Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

First Posted Date
2007-01-19
Last Posted Date
2018-08-31
Lead Sponsor
Northwestern University
Target Recruit Count
9
Registration Number
NCT00424489
Locations
🇺🇸

Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy

First Posted Date
2006-12-13
Last Posted Date
2013-07-01
Lead Sponsor
Armando Santoro, MD
Target Recruit Count
80
Registration Number
NCT00410696
Locations
🇮🇹

Istituto Clinico Humanitas, Rozzano, Milan, Italy

Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

First Posted Date
2006-11-27
Last Posted Date
2017-12-22
Lead Sponsor
George Albert Fisher
Target Recruit Count
21
Registration Number
NCT00404066
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

🇺🇸

Santa Clara Valley Medical Center, San Jose, California, United States

Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

First Posted Date
2006-11-22
Last Posted Date
2015-05-08
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
15
Registration Number
NCT00402558
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath